The pediatric diabetes management market was valued at USD 1.99 Billion in 2025 and is expected to grow at a CAGR of 7.30%, reaching USD 4.03 Billion by 2035. The market growth is driven by the increasing prevalence of type 1 diabetes among children and the growing adoption of advanced insulin delivery systems and continuous glucose monitoring devices. Expanding awareness programs, integration of digital health technologies, and the development of personalized treatment solutions are expected to support market growth during the forecast period.
Base Year
Historical Period
Forecast Period
In July 2025, Biocon Biologics received FDA approval for Kirsty™, the first interchangeable rapid-acting insulin aspart in the U.S. This expands pediatric diabetes treatment options, improving accessibility and driving growth in market.
The market is witnessing strong growth, driven by the increasing prevalence of pediatric diabetes, rising awareness, and the adoption of advanced monitoring and management technologies.
Market expansion is further supported by key players through innovative product development, strategic collaborations, and strengthened distribution channels, enhancing accessibility and improving treatment outcomes for pediatric patients.
Compound Annual Growth Rate
7.3%
Value in USD Billion
2026-2035
*this image is indicative*
Pediatric diabetes management focuses on optimizing care for children with diabetes through personalized treatment plans, continuous glucose monitoring, insulin therapy, and lifestyle interventions to maintain stable blood sugar levels and prevent complications. The market is witnessing steady growth, driven by rising prevalence, technological advancements in monitoring devices, and increasing awareness among caregivers. The market was valued at USD 1.99 Billion in 2025, reflecting significant investment in innovative therapies, digital health solutions, and patient-centric care approaches. Growing healthcare infrastructure and government initiatives further support market expansion, highlighting promising opportunities for industry stakeholders worldwide.
Rising Pediatric Diabetes Prevalence Driving Market Growth
The increasing prevalence of type 2 diabetes among children and adolescents is a significant growth driver for the market. According to Zachary Bloomgarden et al., 2023, the prevalence of Type 2 diabetes in the 10- to 19-year-old population in the United States has doubled over the past two decades. The condition affects nearly 2 per 1,000 Black and American Indian youth, approximately 1 per 1,000 Hispanic youth, and 0.2 per 1,000 non-Hispanic white youth. This rising incidence underscores the growing need for effective pediatric diabetes management solutions, supporting sustained market growth.
Some key market trends include the advancement of automated insulin delivery systems and the rapid expansion of oral therapies.
Advancements in Automated Insulin Delivery Systems to Boost Market Value
Automated insulin delivery (AID) systems are redefining pediatric diabetes care by enabling precise, real-time glucose control for young children with type 1 diabetes. For instance, in July 2025, Medtronic expanded the CE Mark for its MiniMed™ 780G system, allowing use in children as young as two, during pregnancy, and for type 2 diabetes. Clinical data demonstrated improved HbA1c and increased time in range, enhancing quality of life for patients and caregivers. Such technological innovations are expected to accelerate adoption and drive sustained growth in the pediatric diabetes management market.
Expansion of Oral Therapies to Accelerate Pediatric Diabetes Management Market Value
The market is witnessing a significant trend toward the approval and adoption of oral therapies for children and adolescents with type-2 diabetes. In June 2024, the United States Food and Drug Administration approved AstraZeneca’s Farxiga (dapagliflozin) for patients aged 10 years and older, based on robust results from the T2NOW Phase III trial, which demonstrated a significant reduction in A1C levels compared to placebo. This development addresses a long-standing unmet need for effective oral treatments in younger patients. The approval is expected to enhance treatment accessibility and drive sustained market growth globally.
Devices Segment to Witness Substantial Growth
The market includes various product types, primarily medication and devices, each designed to address different aspects of pediatric diabetes management. Medication remains vital for controlling blood glucose levels, while devices include insulin pumps, automated insulin delivery systems, and continuous glucose monitors (CGMs). In June 2025, the news highlighted rapid advancements in diabetes technology, including FDA clearance of systems like Omnipod 5 and Control IQ+, as well as the approval of over-the-counter CGMs. These innovations improve glycemic control, reduce HbA1c, and enhance patient convenience, indicating that devices are expected to lead the market in adoption and growth.
The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, North America is expected to lead during the forecast period due to advanced healthcare infrastructure, a high prevalence of pediatric diabetes, and the rapid adoption of innovative insulin therapies. For instance, in February 2025, the FDA approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar for pediatric and adult patients, underscoring ongoing efforts to enhance access to safe and effective diabetes treatments in the United States.
The key features of the market report comprise clinical trials analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sanofi, a global biopharmaceutical leader, is actively involved in pediatric diabetes management through innovative support and educational initiatives. Their KiDS program focuses on improving diabetes care for children aged 6–14 by promoting disease awareness, healthier lifestyles, and school-based management of type 1 diabetes. Sanofi also offers patient support, educational resources, and access-focused programs, reinforcing its commitment to improving pediatric diabetes outcomes worldwide.
Eli Lilly and Company is a global healthcare leader dedicated to developing medicines that improve lives worldwide. In collaboration with Life for a Child and Beyond Type 1, Lilly provides pediatric diabetes management solutions, including mealtime and basal insulins, reusable pens, blood glucose monitoring, A1C testing, and diabetes education. Through these partnerships, the company expands access to comprehensive diabetes care for children and young people in over 65 countries, supporting equitable healthcare and improved outcomes in resource-limited settings.
Merck & Co., Inc., a global biopharmaceutical leader, focuses on developing innovative therapies to address unmet medical needs. In the pediatric diabetes management space, the company is conducting a Phase 3 clinical trial evaluating ertugliflozin (MK-8835) for children aged 10 to 17 with Type 2 Diabetes Mellitus on metformin, with or without insulin. This study aims to assess the drug’s safety and efficacy in reducing hemoglobin A1C levels, reflecting Merck’s active involvement in advancing treatments for pediatric diabetes.
Bayer AG is a global life sciences company focused on healthcare and nutrition, dedicated to developing innovative therapies that address high unmet medical needs. In pediatric diabetes management, Bayer is advancing treatments through its investigational product, finerenone, a non-steroidal selective mineralocorticoid receptor antagonist. The company is conducting the Phase III FIONA study to evaluate finerenone’s safety and efficacy in children with chronic kidney disease, aiming to improve renal outcomes and complement existing therapies, reflecting Bayer’s commitment to pediatric and cardiovascular care.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Glenmark Pharmaceuticals, GSK plc, F. Hoffmann-La Roche AG, AstraZeneca plc, Pfizer Inc., Novo Nordisk, and Biocon Limited.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Product Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Country
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Product Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share